BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
Where Today's News Shapes Tomorrow
February 25, 2026
Headlines
